This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q1 2025 Earnings Call Transcript May 16, 2025 Operator: Good afternoon, ladies and gentlemen, and welcome to the NRx Pharmaceuticals First Quarter 2025 ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine Provided by PR Newswire May 5, 2025, 12:03:00 PM ...

Company has applied for new Commissioner's National Priority Vouchers (CNPV) for NRX-100. Continues to anticipate decisions on drug approval by year-end 2025Application under CNPV program is ...

About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system ...

NRx Pharmaceuticals (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for treating central nervous system disorders.

NRx Pharmaceuticals (NASDAQ: NRXP) , a clinical-stage biopharmaceutical company, is executing a dual growth strategy focused on expanding its nationa ...

Patent expected to be Orange Book listable, if granted NRX-100, preservative free, IV ketamine, is designed to avoid potential toxicity concerns linked to benzethonium chloride, used in currently ...